China CanSinoBIO’s COVID-19 vaccine trials recruit over 20,000 people 23 AM

BEIJING (Reuters) – China’s CanSino Biologics Inc has recruited over 20,000 participants for late-stage human trials overseas for its coronavirus vaccine, a health official said on Monday.

The candidate, known as Ad5-nCoV or Convidecia, which CanSinoBIO is jointly developing with a research institute backed by the Chinese military, is among the five vaccines China has moved into Phase 3 clinical trials to test their efficacy.…

This news comes via ChinaPulse.com, which delivers news, data, analysis, and insights on Chinese business, travel, finance, health, military, investment, and technology.